Fundz

Casi Pharmaceuticals Acquires Global Intellectual Property Rights To Cleave Therapeutics' Vcp/P97 Inhibitor Cb-5339

PUBLIC · CASIFJul 20, 2023

Acquiring Company

CASI Pharmaceuticals

RockvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.

Other recent acquisitions in Therapeutics and Pharmaceutical

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at CASI Pharmaceuticals, and when

When CASI Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day CASI Pharmaceuticals raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at CASI Pharmaceuticals, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at CASI Pharmaceuticals. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

CASI Pharmaceuticals

Location

Medical Center Drive

Rockville, Maryland, United States

About

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment CASI Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Jim
Senior decision-maker at this company
••••••••@••••••••

See Jim's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for CASI Pharmaceuticals's next move

Learn about Strategic plan

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.